2m 2m 2m 2m 2m 2m 2m
INHIBIKASE THRP (IKT)
NASDAQ
$1.68+$0.005 (+0.30%)
Price as of Jun 03, 2026 4:55 PM EDT- $231.1MMarket Cap
- -15.66%1-Year Change
- BiotechnologyIndustry
INHIBIKASE THRP (IKT)
$1.68+$0.005 (+0.30%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 3.7M N/A | 0 -100.00% | 260,501 +111.03% | 123,440 -96.02% | |
Cost of Revenue | 4.4M 0.00% | 4.4M N/A | N/A N/A | N/A N/A | |
Gross Profit | -684,906 -84.43% | -4.4M -1,789.05% | 260,501 +111.03% | 123,440 -96.02% | |
Sales and Marketing Expense | 23.6M +107.01% | 11.4M +69.02% | 6.7M +8.28% | 6.2M -4.47% | |
Research and Development Expense | -29.8M +73.11% | -17.2M +26.38% | -13.6M +13.16% | -12.0M +5.95% | |
Depreciation and Amortization Expense | 60,499 +130.28% | 26,272 -85.19% | 177,398 +2,538.67% | 6,723 N/A | |
Total Operating Expenses | 52.0M +81.80% | 28.6M +40.48% | 20.4M +11.50% | 18.3M +2.16% | |
Operating Profit | -52.0M +81.80% | -28.6M +42.31% | -20.1M +10.82% | -18.1M +22.77% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 +100.00% | |
Total Nonoperating Income and Expense | 3.7M +247.47% | 1.1M +0.78% | 1.1M +1,324.94% | 74,453 +273.70% | |
Income before Taxes | -52.0M +81.80% | -28.6M +42.31% | -20.1M +10.82% | -18.1M +22.77% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -48.3M +75.36% | -27.5M +44.62% | -19.0M +5.40% | -18.1M +22.10% | |
Net Income from Continuing Operations Applicable to Common | -48.3M +75.36% | -27.5M +44.62% | -19.0M +5.40% | -18.1M +22.10% | |
Basic EPS and Net Income | -0.49 -57.76% | -1.16 -67.51% | -3.57 +395.83% | -0.72 -11.11% | |
Diluted EPS and Net Income | -0.49 -57.76% | -1.16 -67.51% | -3.57 +395.83% | -0.72 -11.11% | |
Basic Weighted Average Shares | 98.3M +314.60% | 23.7M +344.62% | 5.3M -78.85% | 25.2M +38.46% | |
Diluted Weighted Average Shares | 98.3M +314.60% | 23.7M +344.62% | 5.3M -78.85% | 25.2M +38.46% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 139.2M +146.45% | 56.5M +516.36% | 9.2M +27.50% | 7.2M -82.36% | |
Short-Term Investments | 39.5M -3.68% | 41.1M +904.51% | 4.1M -74.23% | 15.9M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 178.8M +83.27% | 97.5M +636.06% | 13.3M -42.51% | 23.1M -43.44% | |
Total Current Assets | 180.1M +82.94% | 98.5M +592.78% | 14.2M -41.69% | 24.4M -42.47% | |
Accumulated Depreciation | 0 -100.00% | 56,725 +86.27% | 30,453 +352.97% | 6,723 N/A | |
Property and Plant and Equipment and Net | 0 -100.00% | 47,100 -35.81% | 73,372 -68.98% | 236,532 N/A | |
Total Long-Term Assets | 95,121 +101.96% | 47,100 -35.81% | 73,372 -68.98% | 236,532 N/A | |
Total Assets | 181.2M +83.78% | 98.6M +579.69% | 14.5M -41.83% | 24.9M -41.28% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 -100.00% | 110,517 -26.37% | 150,095 +2.92% | 145,836 -41.41% | |
Total Current Liabilities | 8.3M +122.33% | 3.7M +8.58% | 3.4M -6.95% | 3.7M -8.85% | |
Total Long-Term Debt | N/A N/A | 0 -100.00% | 763,568 +206.76% | 248,911 N/A | |
Total Long-Term Liabilities | 100 -99.91% | 110,617 -84.47% | 712,127 -11.62% | 805,750 N/A | |
Total Liabilities | 8.3M +122.33% | 3.7M +5.80% | 3.5M -9.54% | 3.9M -3.79% | |
Retained Earnings | -142.7M +51.11% | -94.4M +41.14% | -66.9M +39.75% | -47.9M -260.55% | |
Total Stockholders Equity | 172.9M +82.26% | 94.9M +764.16% | 11.0M -47.81% | 21.0M -45.24% | |
Total Shares Outstanding | 131.7M +89.86% | 69.4M +1,021.23% | 6.2M -75.48% | 25.2M +0.29% | |
Cash Flow | |||||
Cash from Operating Activities | -27.8M +45.11% | -19.1M +5.88% | -18.1M +4.23% | -17.4M +21.36% | |
Capital Expenditures | 13,399 N/A | 0 -100.00% | 14,238 -94.15% | 243,255 N/A | |
Cash from Investing Activities | 2.1M +105.55% | -37.0M -417.45% | 11.7M +172.83% | -16.0M N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 108.5M +4.82% | 103.5M +1,131.14% | 8.4M +4,204.63% | -204,769 -100.50% | |
Financials Ratio | |||||
Gross Margin | -18.44% N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -1,399.00% N/A | N/A N/A | -7,711.98% -47.49% | -14,686.17% N/A | |
Return on Assets | -34.49% -29.11% | -48.66% -49.57% | -96.49% +80.12% | -53.57% N/A | |
Return on Equity | -36.05% -30.68% | -52.00% -56.26% | -118.88% +95.73% | -60.74% N/A | |
Revenue Growth | N/A N/A | -100.00% -190.06% | 111.03% +215.64% | -96.02% N/A | |
Current Ratio | 21.70 -17.72% | 26.37 +538.05% | 4.13 -37.33% | 6.59 N/A | |
Cash Ratio | 16.77 +10.85% | 15.13 +467.66% | 2.67 +37.02% | 1.95 N/A | |
Debt-to-Equity Ratio | N/A N/A | 0.001 -98.56% | 0.08 +342.55% | 0.02 N/A | |
Debt-to-Assets Ratio | N/A N/A | 0.001 -98.25% | 0.06 +298.73% | 0.02 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow